These innovative agents represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://shaniaebel307560.bloggactif.com/40552446/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide